{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:11:05Z","timestamp":1792116665424,"version":"4.4.0"},"reference-count":271,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007505","name":"Kirsten and Freddy Johansens Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007505","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.semcancer.2021.03.035","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T21:58:16Z","timestamp":1617314296000},"page":"163-179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":109,"special_numbering":"C","title":["Multiple endocrine neoplasia type 2: A review"],"prefix":"10.1016","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9770-3188","authenticated-orcid":false,"given":"Jes Sloth","family":"Mathiesen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grigoris","family":"Effraimidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Rossing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c5se Krogh","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"Hoejberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5478-9826","authenticated-orcid":false,"given":"Lars","family":"Bastholt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Godballe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Oturai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5903-3355","authenticated-orcid":false,"given":"Ulla","family":"Feldt-Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.semcancer.2021.03.035_bib0005","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American Thyroid association guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.semcancer.2021.03.035_bib0010","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1530\/EJE-12-0919","article-title":"Molecular epidemiology of multiple endocrine neoplasia 2: implications for RET screening in the new millenium","volume":"168","author":"Machens","year":"2013","journal-title":"Eur. J. Endocrinol. \/ Eur. Federation Endocrine Soc."},{"issue":"12","key":"10.1016\/j.semcancer.2021.03.035_bib0015","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1634\/theoncologist.2014-0277","article-title":"Epidemiology, clinical features, and genetics of multiple endocrine neoplasia type 2B in a complete population","volume":"19","author":"Znaczko","year":"2014","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.semcancer.2021.03.035_bib0020","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1089\/thy.2015.0673","article-title":"A nationwide study of multiple endocrine neoplasia type 2A in Norway: predictive and prognostic factors for the clinical course of medullary thyroid carcinoma","volume":"26","author":"Opsahl","year":"2016","journal-title":"Thyroid"},{"issue":"7","key":"10.1016\/j.semcancer.2021.03.035_bib0025","doi-asserted-by":"crossref","first-page":"L39","DOI":"10.1530\/ERC-17-0122","article-title":"Incidence and prevalence of multiple endocrine neoplasia 2B in Denmark: a nationwide study","volume":"24","author":"Mathiesen","year":"2017","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.semcancer.2021.03.035_bib0030","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2147\/CLEP.S174606","article-title":"Incidence and prevalence of multiple endocrine neoplasia 2A in Denmark 1901-2014: a nationwide study","volume":"10","author":"Mathiesen","year":"2018","journal-title":"Clin. Epidemiol."},{"issue":"7","key":"10.1016\/j.semcancer.2021.03.035_bib0035","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/hmg\/2.7.851","article-title":"Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC","volume":"2","author":"Donis-Keller","year":"1993","journal-title":"Hum. Mol. Genet."},{"issue":"6428","key":"10.1016\/j.semcancer.2021.03.035_bib0040","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/363458a0","article-title":"Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A","volume":"363","author":"Mulligan","year":"1993","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.semcancer.2021.03.035_bib0045","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1073\/pnas.91.4.1579","article-title":"Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B","volume":"91","author":"Carlson","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.semcancer.2021.03.035_bib0050","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/hmg\/3.2.237","article-title":"Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours","volume":"3","author":"Eng","year":"1994","journal-title":"Hum. Mol. Genet."},{"issue":"6461","key":"10.1016\/j.semcancer.2021.03.035_bib0055","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/367375a0","article-title":"A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma","volume":"367","author":"Hofstra","year":"1994","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.semcancer.2021.03.035_bib0060","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/humu.20928","article-title":"Multiple endocrine neoplasia type 2 RET proto-oncogene database: repository of MEN2-associated RET sequence variation and reference for genotype\/phenotype correlations","volume":"30","author":"Margraf","year":"2009","journal-title":"Hum. Mutat."},{"issue":"1","key":"10.1016\/j.semcancer.2021.03.035_bib0065","first-page":"233","article-title":"Prevalence and parental origin of de novo RET mutations in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma. Le Groupe d\u2019Etude des Tumeurs a Calcitonine","volume":"60","author":"Schuffenecker","year":"1997","journal-title":"Am. J. Hum. Genet."},{"issue":"3","key":"10.1016\/j.semcancer.2021.03.035_bib0070","first-page":"213","article-title":"Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study, the lancet","volume":"7","author":"Castinetti","year":"2019","journal-title":"Diabetes Endocrinol."},{"issue":"6","key":"10.1016\/j.semcancer.2021.03.035_bib0075","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1210\/jc.2016-3640","article-title":"Risk profile of the RET A883F germline mutation: an international collaborative study","volume":"102","author":"Mathiesen","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.semcancer.2021.03.035_bib0080","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/0092-8674(85)90115-1","article-title":"Activation of a novel human transforming gene, ret, by DNA rearrangement","volume":"42","author":"Takahashi","year":"1985","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.semcancer.2021.03.035_bib0085","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/(SICI)1096-8628(19981228)80:5<481::AID-AJMG8>3.0.CO;2-6","article-title":"Expression of the RET proto-oncogene in human embryos","volume":"80","author":"Atti\u00e9-Bitach","year":"1998","journal-title":"Am. J. Med. Genet."},{"issue":"4","key":"10.1016\/j.semcancer.2021.03.035_bib0090","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1242\/dev.119.4.1005","article-title":"Expression of the c-ret proto-oncogene during mouse embryogenesis","volume":"119","author":"Pachnis","year":"1993","journal-title":"Development"},{"issue":"10","key":"10.1016\/j.semcancer.2021.03.035_bib0095","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s001090050065","article-title":"Expression of the RET proto-oncogene in normal human tissues, pheochromocytomas, and other tumors of neural crest origin","volume":"74","author":"Takaya","year":"1996","journal-title":"J. Mol. Med. (Berlin, Germany)"},{"issue":"4","key":"10.1016\/j.semcancer.2021.03.035_bib0100","first-page":"1378","article-title":"Ret transforming gene encodes a fusion protein homologous to tyrosine kinases","volume":"7","author":"Takahashi","year":"1987","journal-title":"Mol. Cell. Biol."},{"issue":"5","key":"10.1016\/j.semcancer.2021.03.035_bib0105","first-page":"571","article-title":"Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains","volume":"3","author":"Takahashi","year":"1988","journal-title":"Oncogene"},{"issue":"6585","key":"10.1016\/j.semcancer.2021.03.035_bib0110","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/381785a0","article-title":"Functional receptor for GDNF encoded by the c-ret proto-oncogene","volume":"381","author":"Trupp","year":"1996","journal-title":"Nature"},{"issue":"6585","key":"10.1016\/j.semcancer.2021.03.035_bib0115","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/381789a0","article-title":"GDNF signalling through the Ret receptor tyrosine kinase","volume":"381","author":"Durbec","year":"1996","journal-title":"Nature"},{"issue":"6608","key":"10.1016\/j.semcancer.2021.03.035_bib0120","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/384467a0","article-title":"Neurturin, a relative of glial-cell-line-derived neurotrophic factor","volume":"384","author":"Kotzbauer","year":"1996","journal-title":"Nature"},{"issue":"6586","key":"10.1016\/j.semcancer.2021.03.035_bib0125","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/382080a0","article-title":"Characterization of a multicomponent receptor for GDNF","volume":"382","author":"Treanor","year":"1996","journal-title":"Nature"},{"issue":"4\u20135","key":"10.1016\/j.semcancer.2021.03.035_bib0130","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.cytogfr.2005.05.010","article-title":"RET tyrosine kinase signaling in development and cancer","volume":"16","author":"Arighi","year":"2005","journal-title":"Cytokine Growth Factor Rev."},{"issue":"5196","key":"10.1016\/j.semcancer.2021.03.035_bib0135","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1126\/science.7824936","article-title":"Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B","volume":"267","author":"Santoro","year":"1995","journal-title":"Science (New York, N.Y.)"},{"issue":"20","key":"10.1016\/j.semcancer.2021.03.035_bib0140","doi-asserted-by":"crossref","first-page":"10179","DOI":"10.1158\/0008-5472.CAN-06-0884","article-title":"RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B","volume":"66","author":"Cranston","year":"2006","journal-title":"Cancer Res."},{"issue":"18","key":"10.1016\/j.semcancer.2021.03.035_bib0145","doi-asserted-by":"crossref","first-page":"5572","DOI":"10.1093\/emboj\/16.18.5572","article-title":"Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog","volume":"16","author":"Hubbard","year":"1997","journal-title":"EMBO J."},{"issue":"44","key":"10.1016\/j.semcancer.2021.03.035_bib0150","doi-asserted-by":"crossref","first-page":"33577","DOI":"10.1074\/jbc.M605604200","article-title":"Structure and chemical inhibition of the RET tyrosine kinase domain","volume":"281","author":"Knowles","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.semcancer.2021.03.035_bib0155","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jpedsurg.2009.10.080","article-title":"Familial associations in medullary thyroid carcinoma with Hirschsprung disease: the role of the RET-C620 \u201cJanus\u201d genetic variation","volume":"45","author":"Moore","year":"2010","journal-title":"J. Pediatr. Surg."},{"issue":"3","key":"10.1016\/j.semcancer.2021.03.035_bib0160","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00000658-199409000-00002","article-title":"Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A","volume":"220","author":"Wells","year":"1994","journal-title":"Ann. Surg."},{"issue":"1","key":"10.1016\/j.semcancer.2021.03.035_bib0165","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/ng0194-70","article-title":"Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC","volume":"6","author":"Mulligan","year":"1994","journal-title":"Nat. Genet."},{"issue":"10","key":"10.1016\/j.semcancer.2021.03.035_bib0170","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/hmg\/3.10.1895","article-title":"RET proto-oncogene mutations in inherited and sporadic medullary thyroid cancer","volume":"3","author":"Blaugrund","year":"1994","journal-title":"Hum. Mol. Genet."},{"issue":"3","key":"10.1016\/j.semcancer.2021.03.035_bib0175","first-page":"509","article-title":"A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC","volume":"10","author":"Eng","year":"1995","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.semcancer.2021.03.035_bib0180","first-page":"2063","article-title":"The RET protooncogene in sporadic pheochromocytomas: frequent MEN 2-like mutations and new molecular defects","volume":"80","author":"Beldjord","year":"1995","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"12","key":"10.1016\/j.semcancer.2021.03.035_bib0185","first-page":"2415","article-title":"RET mutations in exons 13 and 14 of FMTC patients","volume":"10","author":"Bolino","year":"1995","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.semcancer.2021.03.035_bib0190","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/(SICI)1097-0215(19960822)69:4<312::AID-IJC13>3.0.CO;2-7","article-title":"Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET proto-oncogene. \u201cStudy Group Multiple Endocrine Neoplasia Austria (SMENA)\u201d","volume":"69","author":"Fink","year":"1996","journal-title":"Int. J. Cancer Suppl."},{"issue":"1","key":"10.1016\/j.semcancer.2021.03.035_bib0195","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/(SICI)1098-1004(1996)8:1<64::AID-HUMU9>3.0.CO;2-P","article-title":"Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET proto-oncogene mutations","volume":"8","author":"Kambouris","year":"1996","journal-title":"Hum. Mutat."},{"issue":"5","key":"10.1016\/j.semcancer.2021.03.035_bib0200","first-page":"1780","article-title":"Mutations of the ret protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype","volume":"81","author":"Frank-Raue","year":"1996","journal-title":"German Medullary Thyroid Carcinoma Study Group, The Journal of clinical endocrinology and metabolism"},{"issue":"12","key":"10.1016\/j.semcancer.2021.03.035_bib0205","first-page":"4176","article-title":"A novel point mutation in the intracellular domain of the ret protooncogene in a family with medullary thyroid carcinoma","volume":"82","author":"Hofstra","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"25","key":"10.1016\/j.semcancer.2021.03.035_bib0210","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1038\/sj.onc.1201102","article-title":"Novel germline RET proto-oncogene mutations associated with medullary thyroid carcinoma (MTC): mutation analysis in Japanese patients with MTC","volume":"14","author":"Kitamura","year":"1997","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.semcancer.2021.03.035_bib0215","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/clinchem\/43.3.453","article-title":"Rapid, nonradioactive screening for mutations in exons 10, 11, and 16 of the RET protooncogene associated with inherited medullary thyroid carcinoma","volume":"43","author":"Siegelman","year":"1997","journal-title":"Clin. Chem."},{"issue":"10","key":"10.1016\/j.semcancer.2021.03.035_bib0220","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/sj.onc.1201481","article-title":"Germline mutation of RET codon 883 in two cases of de novo MEN 2B","volume":"15","author":"Smith","year":"1997","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.semcancer.2021.03.035_bib0225","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/(SICI)1096-8628(19980707)78:3<271::AID-AJMG13>3.0.CO;2-C","article-title":"Novel point mutation in exon 10 of the RET proto-oncogene in a family with medullary thyroid carcinoma","volume":"78","author":"Oriola","year":"1998","journal-title":"Am. J. Med. Genet."},{"issue":"3","key":"10.1016\/j.semcancer.2021.03.035_bib0230","first-page":"770","article-title":"A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A","volume":"83","author":"Berndt","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.semcancer.2021.03.035_bib0235","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1677\/joe.0.1700661","article-title":"Molecular genetic diagnostic program of multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma syndromes in Hungary","volume":"170","author":"Klein","year":"2001","journal-title":"J.Endocrinol."},{"issue":"11","key":"10.1016\/j.semcancer.2021.03.035_bib0240","doi-asserted-by":"crossref","first-page":"5438","DOI":"10.1210\/jc.2003-030997","article-title":"A novel germ-line point mutation in RET exon 8 (Gly(533)Cys) in a large kindred with familial medullary thyroid carcinoma","volume":"88","author":"Da Silva","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"16","key":"10.1016\/j.semcancer.2021.03.035_bib0245","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa012915","article-title":"Early malignant progression of hereditary medullary thyroid cancer","volume":"349","author":"Machens","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.semcancer.2021.03.035_bib0250","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1210\/jc.2004-0073","article-title":"A novel point mutation of the RET protooncogene involving the second intracellular tyrosine kinase domain in a family with medullary thyroid carcinoma","volume":"89","author":"Jimenez","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.semcancer.2021.03.035_bib0255","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S1525-1578(10)60556-9","article-title":"Nine novel germline gene variants in the RET proto-oncogene identified in twelve unrelated cases","volume":"7","author":"Ahmed","year":"2005","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.semcancer.2021.03.035_bib0260","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3389\/fendo.2018.00398","article-title":"Medullary thyroid carcinoma with exon 2 p.L56M RET variant: clinical particular features in two patients","volume":"9","author":"Paragliola","year":"2018","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"4","key":"10.1016\/j.semcancer.2021.03.035_bib0265","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1210\/jc.2017-02402","article-title":"A homozygous RET K666N genotype with an MEN2A phenotype","volume":"103","author":"Jaber","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2021.03.035_bib0270","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejca.2017.06.007","article-title":"Germline polymorphisms on RET proto-oncogene involved in medullary thyroid carcinoma in a Druze family","volume":"82","author":"Azzam","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.semcancer.2021.03.035_bib0275","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/00000658-200211000-00006","article-title":"Various penetrance of familial medullary thyroid carcinoma in patients with RET protooncogene codon 790\/791 germline mutations","volume":"236","author":"Fitze","year":"2002","journal-title":"Ann.Surg."},{"issue":"10","key":"10.1016\/j.semcancer.2021.03.035_bib0280","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1007\/s00268-002-6487-1","article-title":"Surgical strategy in a kindred with a rare RET protooncogene mutation of variable penetrance with regard to multiple endocrine neoplasia","volume":"26","author":"Colombo-Benkmann","year":"2002","journal-title":"World J. Surg."},{"issue":"6","key":"10.1016\/j.semcancer.2021.03.035_bib0285","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/j.1365-2265.2011.04158.x","article-title":"Germline RET sequence variation I852M and occult medullary thyroid cancer: harmless polymorphism or causative mutation?","volume":"75","author":"Machens","year":"2011","journal-title":"Clin. Endocrinol."},{"issue":"8","key":"10.1016\/j.semcancer.2021.03.035_bib0290","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1089\/thy.2017.0131","article-title":"Novel somatic RET mutation questioning the causality of the RET I852M germline sequence variant in multiple endocrine neoplasia 2A","volume":"27","author":"Mathiesen","year":"2017","journal-title":"Thyroid"},{"issue":"6","key":"10.1016\/j.semcancer.2021.03.035_bib0295","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/jso.25371","article-title":"Long-term follow-up of RET Y791F carriers in Denmark 1994-2017: a national cohort study","volume":"119","author":"Hoxbroe Michaelsen","year":"2019","journal-title":"J. Surg. Oncol."},{"issue":"11","key":"10.1016\/j.semcancer.2021.03.035_bib0300","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1210\/jc.2017-02529","article-title":"p.Val804Met, the most frequent pathogenic mutation in RET, confers a very low lifetime risk of medullary thyroid cancer","volume":"103","author":"Loveday","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"10.1016\/j.semcancer.2021.03.035_bib0305","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1089\/thy.2013.0620","article-title":"Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutations","volume":"24","author":"Rich","year":"2014","journal-title":"Thyroid"},{"key":"10.1016\/j.semcancer.2021.03.035_bib0310","first-page":"139","article-title":"Hereditary medullary thyroid Cancer genotype-Phenotype correlation, recent results in cancer research","volume":"204","author":"Frank-Raue","year":"2015","journal-title":"Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer"},{"issue":"Suppl 1","key":"10.1016\/j.semcancer.2021.03.035_bib0315","doi-asserted-by":"crossref","first-page":"69","DOI":"10.6061\/clinics\/2012(Sup01)13","article-title":"Genotype-phenotype correlation in multiple endocrine neoplasia type 2","volume":"67","author":"Raue","year":"2012","journal-title":"Clinics.(Sao Paulo)"},{"issue":"3","key":"10.1016\/j.semcancer.2021.03.035_bib0320","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/jjco\/27.3.128","article-title":"A nationwide clinical survey of patients with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma in Japan","volume":"27","author":"Iihara","year":"1997","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.semcancer.2021.03.035_bib0325","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2796.1995.tb01211.x","article-title":"Pheochromocytoma in multiple endocrine neoplasia type 2: european study. The Euromen Study Group","volume":"238","author":"Modigliani","year":"1995","journal-title":"J. Intern. Med."},{"issue":"9","key":"10.1016\/j.semcancer.2021.03.035_bib0330","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJM197308302890901","article-title":"C-cell hyperplasia preceding medullary thyroid carcinoma","volume":"289","author":"Wolfe","year":"1973","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.semcancer.2021.03.035_bib0335","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/humu.23430","article-title":"Genotype-specific progression of hereditary medullary thyroid cancer","volume":"39","author":"Machens","year":"2018","journal-title":"Hum. Mutat."},{"issue":"5","key":"10.1016\/j.semcancer.2021.03.035_bib0340","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1530\/EJE-08-0854","article-title":"Medullary thyroid carcinoma identified within the first year of life in children with hereditary multiple endocrine neoplasia type 2A (codon 634) and 2B","volume":"160","author":"Zenaty","year":"2009","journal-title":"Eur. J. endocrinol.\/ Eur. Federation Endocrine Soc."},{"issue":"3","key":"10.1016\/j.semcancer.2021.03.035_bib0345","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1046\/j.1365-2265.1998.00392.x","article-title":"Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d\u2019etude des tumeurs a calcitonine","volume":"48","author":"Modigliani","year":"1998","journal-title":"Clin. Endocrinol."},{"issue":"3","key":"10.1016\/j.semcancer.2021.03.035_bib0350","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1089\/thy.2018.0564","article-title":"Survival and long-term biochemical cure in medullary thyroid carcinoma in Denmark 1997-2014: a nationwide study","volume":"29","author":"Mathiesen","year":"2019","journal-title":"Thyroid"},{"issue":"2","key":"10.1016\/j.semcancer.2021.03.035_bib0355","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1001\/archsurg.1980.01380020012004","article-title":"Clinical characteristics distinguishing hereditary from sporadic medullary thyroid carcinoma. Treatment implications","volume":"115","author":"Block","year":"1980","journal-title":"Arch.Surg."},{"issue":"6","key":"10.1016\/j.semcancer.2021.03.035_bib0360","first-page":"1070","article-title":"Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia type 2A: results of long-term follow-up","volume":"114","author":"Howe","year":"1993","journal-title":"Surgery"},{"issue":"7","key":"10.1016\/j.semcancer.2021.03.035_bib0365","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1210\/jc.2005-0064","article-title":"Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2","volume":"90","author":"Machens","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.semcancer.2021.03.035_bib0370","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.surg.2007.09.013","article-title":"Pheochromocytoma penetrance varies by RET mutation in MEN 2A","volume":"142","author":"Quayle","year":"2007","journal-title":"Surgery"},{"issue":"5","key":"10.1016\/j.semcancer.2021.03.035_bib0375","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1530\/EJE-12-1106","article-title":"High penetrance of pheochromocytoma in multiple endocrine neoplasia 2 caused by germ line RET codon 634 mutation in Japanese patients","volume":"168","author":"Imai","year":"2013","journal-title":"Eur. J. endocrinol.\/ Eur. Federation Endocrine Soc."},{"issue":"1","key":"10.1016\/j.semcancer.2021.03.035_bib0380","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/humu.21385","article-title":"Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10","volume":"32","author":"Frank-Raue","year":"2011","journal-title":"Hum. Mutat."},{"issue":"11","key":"10.1016\/j.semcancer.2021.03.035_bib0385","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1007\/s00268-008-9734-2","article-title":"Pheochromocytoma in MEN 2A syndrome. Study of 54 patients","volume":"32","author":"Rodriguez","year":"2008","journal-title":"World J. Surg."},{"issue":"1","key":"10.1016\/j.semcancer.2021.03.035_bib0390","doi-asserted-by":"crossref","first-page":"54","DOI":"10.5603\/EP.2016.0008","article-title":"Occurrence of phaeochromocytoma tumours in RET mutation carriers - a single-centre study","volume":"67","author":"Kotecka-Blicharz","year":"2016","journal-title":"Endokrynol. Pol."},{"issue":"2","key":"10.1016\/j.semcancer.2021.03.035_bib0395","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s12020-020-02232-5","article-title":"100-Year evolution of precision medicine and surgery for multiple endocrine neoplasia type 2A","volume":"68","author":"Machens","year":"2020","journal-title":"Endocrine"},{"issue":"6","key":"10.1016\/j.semcancer.2021.03.035_bib0400","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/00000658-199306000-00001","article-title":"Management of pheochromocytomas in patients with multiple endocrine neoplasia type 2 syndromes","volume":"217","author":"Lairmore","year":"1993","journal-title":"Ann. Surg."},{"issue":"5","key":"10.1016\/j.semcancer.2021.03.035_bib0405","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1365-2265.1993.tb00350.x","article-title":"Phaeochromocytoma in multiple endocrine neoplasia type 2 A: survey of 100 cases","volume":"38","author":"Casanova","year":"1993","journal-title":"Clin. Endocrinol. (Oxf)"},{"issue":"11","key":"10.1016\/j.semcancer.2021.03.035_bib0410","doi-asserted-by":"crossref","first-page":"E1813","DOI":"10.1210\/jc.2013-1653","article-title":"The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2","volume":"98","author":"Thosani","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.semcancer.2021.03.035_bib0415","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/jso.23378","article-title":"Pheochromocytoma in an 8-year-old patient with multiple endocrine neoplasia type 2A: implications for screening","volume":"108","author":"Rowland","year":"2013","journal-title":"J. Surg. Oncol."},{"issue":"3","key":"10.1016\/j.semcancer.2021.03.035_bib0420","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1530\/EJE-14-0818","article-title":"RET Cys634Arg mutation confers a more aggressive multiple endocrine neoplasia type 2A phenotype than Cys634Tyr mutation","volume":"172","author":"Valdes","year":"2015","journal-title":"Eur. J. endocrinol.\/ Eur. Federation Endocrine Soc."},{"issue":"11","key":"10.1016\/j.semcancer.2021.03.035_bib0425","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1017\/S0022215100145761","article-title":"Paraganglioma as a systemic syndrome: pitfalls and strategies","volume":"113","author":"Maier","year":"1999","journal-title":"J. Laryngol. Otol."},{"issue":"17","key":"10.1016\/j.semcancer.2021.03.035_bib0430","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1001\/jama.281.17.1587","article-title":"Adrenal and extra-adrenal pheochromocytomas in a family with germline RET V804L mutation","volume":"281","author":"Nilsson","year":"1999","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.semcancer.2021.03.035_bib0435","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1210\/jc.2009-0354","article-title":"Head and neck paragangliomas in von Hippel-Lindau disease and multiple endocrine neoplasia type 2","volume":"94","author":"Boedeker","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.semcancer.2021.03.035_bib0440","doi-asserted-by":"crossref","first-page":"E336","DOI":"10.1210\/jc.2012-3192","article-title":"Peak incidence of pheochromocytoma and primary hyperparathyroidism in multiple endocrine neoplasia 2: need for age-adjusted biochemical screening","volume":"98","author":"Machens","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.semcancer.2021.03.035_bib0445","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S1470-2045(14)70154-8","article-title":"Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study","volume":"15","author":"Castinetti","year":"2014","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.semcancer.2021.03.035_bib0450","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/cen.13386","article-title":"Phaeochromocytoma in multiple endocrine neoplasia type 2: RET codon-specific penetrance and changes in management during the last four decades","volume":"87","author":"Mucha","year":"2017","journal-title":"Clin. Endocrinol. (Oxf)"},{"issue":"2","key":"10.1016\/j.semcancer.2021.03.035_bib0455","first-page":"487","article-title":"Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. Groupe D\u2019etude des Tumeurs a Calcitonine","volume":"83","author":"Schuffenecker","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"10.1016\/j.semcancer.2021.03.035_bib0460","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1007\/s002689900123","article-title":"Primary hyperparathyroidism in multiple endocrine neoplasia type IIa: retrospective French multicentric study. Groupe d\u2019Etude des Tumeurs a Calcitonine (GETC, French Calcitonin Tumors Study Group), French Association of Endocrine Surgeons","volume":"20","author":"Kraimps","year":"1996","journal-title":"World J. Surg."},{"issue":"6","key":"10.1016\/j.semcancer.2021.03.035_bib0465","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0039-6060(96)80042-0","article-title":"Surgical management of hyperparathyroidism in patients with multiple endocrine neoplasia type 2A","volume":"120","author":"Herfarth","year":"1996","journal-title":"Surgery"},{"issue":"4","key":"10.1016\/j.semcancer.2021.03.035_bib0470","first-page":"362","article-title":"[Multiple endocrine neoplasia type 2 in Japan: large-scale analysis of data from the MEN consortium of Japan]","volume":"113","author":"Uchino","year":"2012","journal-title":"Nihon Geka Gakkai Zasshi"},{"key":"10.1016\/j.semcancer.2021.03.035_bib0475","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1750-1172-8-50","article-title":"Differences between sporadic and MEN related primary hyperparathyroidism; clinical expression, preoperative workup, operative strategy and follow-up","volume":"8","author":"Twigt","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"issue":"4","key":"10.1016\/j.semcancer.2021.03.035_bib0480","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2796.1995.tb01212.x","article-title":"Primary hyperparathyroidism in multiple endocrine neoplasia type 2A","volume":"238","author":"Raue","year":"1995","journal-title":"J. Intern. Med."},{"issue":"6","key":"10.1016\/j.semcancer.2021.03.035_bib0485","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1530\/EC-20-0163","article-title":"Primary hyperparathyroidism as first manifestation in multiple endocrine neoplasia type 2A: an international multicenter study","volume":"9","author":"Larsen","year":"2020","journal-title":"Endocr. Connect."},{"issue":"5","key":"10.1016\/j.semcancer.2021.03.035_bib0490","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1089\/thy.2010.0336","article-title":"Primary hyperparathyroidism as the first clinical manifestation of multiple endocrine neoplasia type 2A in a 5-year-old child","volume":"21","author":"Magalhaes","year":"2011","journal-title":"Thyroid"},{"issue":"Suppl 1","key":"10.1016\/j.semcancer.2021.03.035_bib0495","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1186\/1756-6614-6-S1-S10","article-title":"Management of hyperparathyroidism (PHP) in MEN2 syndromes in Europe","volume":"6","author":"Alevizaki","year":"2013","journal-title":"Thyroid Res."},{"issue":"6","key":"10.1016\/j.semcancer.2021.03.035_bib0500","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1046\/j.1365-2265.1997.3421147.x","article-title":"Metastatic parathyroid carcinoma in the MEN2A syndrome","volume":"47","author":"Jenkins","year":"1997","journal-title":"Clin. Endocrinol."},{"issue":"2","key":"10.1016\/j.semcancer.2021.03.035_bib0505","doi-asserted-by":"crossref","first-page":"T15","DOI":"10.1530\/ERC-17-0266","article-title":"Looking beyond the thyroid: advances in the understanding of pheochromocytoma and hyperparathyroidism phenotypes in MEN2 and of non-MEN2 familial forms","volume":"25","author":"Guerin","year":"2018","journal-title":"Endocr. Relat. Cancer"},{"issue":"4","key":"10.1016\/j.semcancer.2021.03.035_bib0510","doi-asserted-by":"crossref","DOI":"10.1007\/s10689-016-9892-6","article-title":"MEN 2A-related cutaneous lichen amyloidosis: report of three kindred and systematic literature review of clinical, biochemical and molecular characteristics","volume":"15","author":"Scapineli","year":"2016","journal-title":"Fam. Cancer"},{"issue":"6","key":"10.1016\/j.semcancer.2021.03.035_bib0515","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1089\/thy.2009.0021","article-title":"Familial medullary thyroid carcinoma associated with cutaneous lichen amyloidosis","volume":"19","author":"Rothberg","year":"2009","journal-title":"Thyroid"},{"issue":"9","key":"10.1016\/j.semcancer.2021.03.035_bib0520","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1530\/EC-18-0220","article-title":"The RET C611Y mutation causes MEN 2A and associated cutaneous","volume":"7","author":"Qi","year":"2018","journal-title":"Endocr. Connect."},{"issue":"3\u20134","key":"10.1016\/j.semcancer.2021.03.035_bib0525","first-page":"249","article-title":"Characterization of the clinical features of five families with hereditary primary cutaneous lichen amyloidosis and multiple endocrine neoplasia type 2","volume":"40","author":"Robinson","year":"1992","journal-title":"Henry Ford Hosp. Med. J."},{"issue":"3\u20134","key":"10.1016\/j.semcancer.2021.03.035_bib0530","first-page":"147","article-title":"Familial cutaneous lichen amyloidosis in association with multiple endocrine neoplasia type 2A: a new variant","volume":"37","author":"Donovan","year":"1989","journal-title":"Henry Ford Hosp. Med. J."},{"issue":"2","key":"10.1016\/j.semcancer.2021.03.035_bib0535","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/1523-1747.ep12329651","article-title":"RET mutation screening in familial cutaneous lichen amyloidosis and in skin amyloidosis associated with multiple endocrine neoplasia","volume":"107","author":"Hofstra","year":"1996","journal-title":"J. Invest. Dermatol."},{"issue":"2","key":"10.1016\/j.semcancer.2021.03.035_bib0540","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/07357907.2018.1430813","article-title":"The clinical Spectrum of multiple endocrine neoplasia type 2A with cutaneous lichen amyloidosis in ethnic Han Chinese","volume":"36","author":"Qi","year":"2018","journal-title":"Cancer Invest."},{"issue":"2","key":"10.1016\/j.semcancer.2021.03.035_bib0545","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1046\/j.1365-2265.2003.01782.x","article-title":"Frequent association between MEN 2A and cutaneous lichen amyloidosis","volume":"59","author":"Verga","year":"2003","journal-title":"Clin. Endocrinol."},{"issue":"4","key":"10.1016\/j.semcancer.2021.03.035_bib0550","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1530\/eje.0.1390410","article-title":"Germ line mutation analysis in families with multiple endocrine neoplasia type 2A or familial medullary thyroid carcinoma","volume":"139","author":"Karga","year":"1998","journal-title":"Eur. J. endocrinol.\/ Eur. Federation Endocrine Soc."},{"issue":"3\u20134","key":"10.1016\/j.semcancer.2021.03.035_bib0555","first-page":"144","article-title":"Cutaneous lichen amyloidosis associated with multiple endocrine neoplasia type 2A","volume":"37","author":"Nunziata","year":"1989","journal-title":"Henry Ford Hosp. Med. J."},{"issue":"8","key":"10.1016\/j.semcancer.2021.03.035_bib0560","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00383-014-3538-2","article-title":"The association between Hirschsprung\u2019s disease and multiple endocrine neoplasia type 2a: a systematic review","volume":"30","author":"Coyle","year":"2014","journal-title":"Pediatr. Surg. Int."},{"issue":"11","key":"10.1016\/j.semcancer.2021.03.035_bib0565","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.4158\/EP15838.OR","article-title":"A novel double mutation VAL648ILE and VAL804LEU of ret proto-oncogene in multiple endocrine neoplasia type 2","volume":"21","author":"Verrienti","year":"2015","journal-title":"Endocr. Pract."},{"issue":"5","key":"10.1016\/j.semcancer.2021.03.035_bib0570","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/00000658-200205000-00006","article-title":"Gastrointestinal manifestations of multiple endocrine neoplasia type 2","volume":"235","author":"Cohen","year":"2002","journal-title":"Ann. Surg."},{"issue":"1","key":"10.1016\/j.semcancer.2021.03.035_bib0575","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jpedsurg.2007.09.043","article-title":"RET proto-oncogene testing in infants presenting with Hirschsprung disease identifies 2 new multiple endocrine neoplasia 2A kindreds","volume":"43","author":"Fialkowski","year":"2008","journal-title":"J. Pediatr. Surg."},{"issue":"2","key":"10.1016\/j.semcancer.2021.03.035_bib0580","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jpedsurg.2006.10.005","article-title":"Familial medullary carcinoma prevention, risk evaluation, and RET in children of families with MEN2","volume":"42","author":"Moore","year":"2007","journal-title":"J. Pediatr. Surg."},{"issue":"2","key":"10.1016\/j.semcancer.2021.03.035_bib0585","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0022-3468(98)90433-X","article-title":"Occurrence of MEN 2a in familial Hirschsprung\u2019s disease: a new indication for genetic testing of the RET proto-oncogene","volume":"33","author":"Decker","year":"1998","journal-title":"J. Pediatr. Surg."},{"issue":"12","key":"10.1016\/j.semcancer.2021.03.035_bib0590","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1093\/hmg\/3.12.2163","article-title":"Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene","volume":"3","author":"Mulligan","year":"1994","journal-title":"Hum. Mol. Genet."},{"issue":"1","key":"10.1016\/j.semcancer.2021.03.035_bib0595","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/hmg\/7.1.129","article-title":"Hirschsprung disease in MEN 2A: increased spectrum of RET exon 10 genotypes and strong genotype-phenotype correlation","volume":"7","author":"Decker","year":"1998","journal-title":"Hum. Mol. Genet."},{"issue":"19","key":"10.1016\/j.semcancer.2021.03.035_bib0600","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1001\/jama.1996.03540190047028","article-title":"The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis","volume":"276","author":"Eng","year":"1996","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.semcancer.2021.03.035_bib0605","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/bjs.1800730411","article-title":"Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity","volume":"73","author":"Farndon","year":"1986","journal-title":"Br.J.Surg."},{"issue":"6","key":"10.1016\/j.semcancer.2021.03.035_bib0610","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1089\/thy.2008.0403","article-title":"Medullary thyroid cancer: management guidelines of the American Thyroid Association","volume":"19","author":"Kloos","year":"2009","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.semcancer.2021.03.035_bib0615","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/path.1700910109","article-title":"Multiple mucosal neuromata with endocrine tumours: a syndrome allied to von Recklinghausen\u2019s disease","volume":"91","author":"Williams","year":"1966","journal-title":"J. Pathol. Bacteriol."},{"issue":"2","key":"10.1016\/j.semcancer.2021.03.035_bib0620","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/1097-0142(196808)22:2<293::AID-CNCR2820220206>3.0.CO;2-R","article-title":"Multiple mucosal neuromas, pheochromocytoma and medullary carcinoma of the thyroid--a syndrome","volume":"22","author":"Gorlin","year":"1968","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.semcancer.2021.03.035_bib0625","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1365-2265.1995.tb00547.x","article-title":"No mutation at codon 918 of the RET gene in a family with multiple endocrine neoplasia type 2B","volume":"43","author":"Toogood","year":"1995","journal-title":"Clin. Endocrinol."},{"issue":"11","key":"10.1016\/j.semcancer.2021.03.035_bib0630","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1210\/jcem.82.11.4508","article-title":"Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation","volume":"82","author":"Gimm","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.semcancer.2021.03.035_bib0635","first-page":"1","article-title":"Two germline missense mutations at codons 804 and 806 of the RET proto-oncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation, Japanese journal of cancer research","volume":"90","author":"Miyauchi","year":"1999","journal-title":"Gann"},{"issue":"December (12)","key":"10.1016\/j.semcancer.2021.03.035_bib0640","first-page":"E363","article-title":"Novel tandem germline RET proto-oncogene mutations in a patient with multiple endocrine neoplasia type 2B: report of a case and a literature review of tandem RET mutations with in silico analysis","volume":"35","author":"Nakao","year":"2013","journal-title":"Report], Head & Neck"},{"issue":"2","key":"10.1016\/j.semcancer.2021.03.035_bib0645","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1089\/thy.2019.0472","article-title":"A novel double RET E768D\/L790F mutation associated with a MEN2B-Like phenotype","volume":"31","author":"Mathew","year":"2021","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.semcancer.2021.03.035_bib0650","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1687-9856-2012-25","article-title":"Medullary thyroid cancer in a 9-week-old infant with familial MEN 2B: implications for timing of prophylactic thyroidectomy","volume":"2012","author":"Shankar","year":"2012","journal-title":"Int. J. Pediatr. Endocrinol."},{"issue":"9","key":"10.1016\/j.semcancer.2021.03.035_bib0655","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.jpedsurg.2007.05.015","article-title":"Medullary thyroid carcinoma in a 2-month-old male with multiple endocrine neoplasia 2B and symptoms of pseudo-Hirschsprung disease: a case report","volume":"42","author":"Unruh","year":"2007","journal-title":"J. Pediatr. Surg."},{"issue":"4","key":"10.1016\/j.semcancer.2021.03.035_bib0660","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/SLA.0b013e3182a6f43a","article-title":"Surgical curability of medullary thyroid cancer in multiple endocrine neoplasia 2B: a changing perspective","volume":"259","author":"Brauckhoff","year":"2014","journal-title":"Ann. Surg."},{"issue":"1","key":"10.1016\/j.semcancer.2021.03.035_bib0665","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1210\/jc.2018-00705","article-title":"Pheochromocytoma in children and adolescents with multiple endocrine neoplasia type 2B","volume":"104","author":"Makri","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.semcancer.2021.03.035_bib0670","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1210\/jc.2017-01884","article-title":"Long-term survivorship in multiple endocrine neoplasia type 2B diagnosed before and in the new millennium","volume":"103","author":"Raue","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.semcancer.2021.03.035_bib0675","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.surg.2008.08.028","article-title":"Premonitory symptoms preceding metastatic medullary thyroid cancer in MEN 2B: an exploratory analysis","volume":"144","author":"Brauckhoff","year":"2008","journal-title":"Surgery"},{"issue":"2","key":"10.1016\/j.semcancer.2021.03.035_bib0680","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28056","article-title":"Multiple endocrine neoplasia type 2B: frequency of physical stigmata-Results of the GPOH-MET registry","volume":"67","author":"Redlich","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.semcancer.2021.03.035_bib0685","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jpeds.2018.08.022","article-title":"Multiple endocrine neoplasia type 2B presents early in childhood but often is undiagnosed for years","volume":"203","author":"Makri","year":"2018","journal-title":"J. Pediatr."},{"issue":"1","key":"10.1016\/j.semcancer.2021.03.035_bib0690","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1245\/s10434-007-9665-4","article-title":"Failure to recognize multiple endocrine neoplasia 2B: more common than we think?","volume":"15","author":"Wray","year":"2008","journal-title":"Ann. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2021.03.035_bib0695","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1089\/thy.2014.0177","article-title":"Aggressive medullary thyroid carcinoma in a ten-year-old patient with multiple endocrine neoplasia 2B due to the A883F mutation","volume":"25","author":"Mathiesen","year":"2015","journal-title":"Thyroid"},{"issue":"4","key":"10.1016\/j.semcancer.2021.03.035_bib0700","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1365-2796.1995.tb01208.x","article-title":"Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium","volume":"238","author":"Mulligan","year":"1995","journal-title":"J. Intern. Med."},{"issue":"4","key":"10.1016\/j.semcancer.2021.03.035_bib0705","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1677\/ERC-08-0105","article-title":"Age-related neoplastic risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germ line RET Cys634Trp (TGC&TGG) mutation","volume":"15","author":"Milos","year":"2008","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.semcancer.2021.03.035_bib0710","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3389\/fendo.2020.00251","article-title":"Variability in medullary thyroid carcinoma in RET L790F carriers: a case comparison study of index patients","volume":"11","author":"Mathiesen","year":"2020","journal-title":"Front. Endocrinol."},{"issue":"2","key":"10.1016\/j.semcancer.2021.03.035_bib0715","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s10689-016-9948-7","article-title":"All in the family? Analyzing the impact of family history in addition to genotype on medullary thyroid carcinoma aggressiveness in MEN2A patients","volume":"16","author":"Long","year":"2017","journal-title":"Fam. Cancer"},{"issue":"12","key":"10.1016\/j.semcancer.2021.03.035_bib0720","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1530\/ERC-16-0141","article-title":"M918V RET mutation causes familial medullary thyroid carcinoma: study of 8 affected kindreds","volume":"23","author":"Martins-Costa","year":"2016","journal-title":"Endocr. Relat. Cancer"},{"issue":"2","key":"10.1016\/j.semcancer.2021.03.035_bib0725","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/cen.12264","article-title":"A ten-year clinical update of a large RET p.Gly533Cys kindred with medullary thyroid carcinoma emphasizes the need for an individualized assessment of affected relatives","volume":"80","author":"Signorini","year":"2014","journal-title":"Clin. Endocrinol."},{"issue":"3","key":"10.1016\/j.semcancer.2021.03.035_bib0730","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1530\/EJE-13-0050","article-title":"The clinical spectrum of RET proto-oncogene mutations in codon 790","volume":"169","author":"Bihan","year":"2013","journal-title":"Eur. J. endocrinol.\/ Eur. Federation Endocrine Soc."},{"issue":"5","key":"10.1016\/j.semcancer.2021.03.035_bib0735","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2265.2006.02509.x","article-title":"A rare RET gene exon 8 mutation is found in two Greek kindreds with familial medullary thyroid carcinoma: implications for screening","volume":"64","author":"Kaldrymides","year":"2006","journal-title":"Clin. Endocrinol."},{"issue":"6","key":"10.1016\/j.semcancer.2021.03.035_bib0740","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/bjs.4457","article-title":"Phenotypic expression of a family with multiple endocrine neoplasia type 2A due to a RET mutation at codon 618","volume":"91","author":"Lindskog","year":"2004","journal-title":"Br. J. Surg."},{"issue":"4","key":"10.1016\/j.semcancer.2021.03.035_bib0745","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1210\/jcem.87.4.8403","article-title":"Familial medullary thyroid carcinoma: clinical variability and low aggressiveness associated with RET mutation at codon 804","volume":"87","author":"Lombardo","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.semcancer.2021.03.035_bib0750","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1067\/msy.2000.107103","article-title":"Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to a RET V804M (GTG--&ATG) mutation","volume":"128","author":"Feldman","year":"2000","journal-title":"Surgery"},{"issue":"4","key":"10.1016\/j.semcancer.2021.03.035_bib0755","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1530\/ERC-17-0452","article-title":"Modifying impact of RET gene haplotypes on medullary thyroid carcinoma clinical course","volume":"25","author":"Kaczmarek-Rys","year":"2018","journal-title":"Endocr. Relat. Cancer"},{"issue":"3","key":"10.1016\/j.semcancer.2021.03.035_bib0760","first-page":"152","article-title":"Rare RET variant p.D707E in a chinese pedigree with hereditary medullary thyroid carcinoma, pathobiology\u202f: journal of immunopathology","volume":"84","author":"Zhang","year":"2017","journal-title":"Mol. Cell. Biol."},{"issue":"12","key":"10.1016\/j.semcancer.2021.03.035_bib0765","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1089\/thy.2016.0399","article-title":"Nationwide french study of RET variants detected from 2003 to 2013 suggests a possible influence of polymorphisms as modifiers","volume":"27","author":"Lebeault","year":"2017","journal-title":"Thyroid"},{"key":"10.1016\/j.semcancer.2021.03.035_bib0770","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13023-015-0231-z","article-title":"The modifier role of RET-G691S polymorphism in hereditary medullary thyroid carcinoma: functional characterization and expression\/penetrance studies","volume":"10","author":"Colombo","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"issue":"6","key":"10.1016\/j.semcancer.2021.03.035_bib0775","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1530\/EJE-14-0084","article-title":"Role of RET genetic variants in MEN2-associated pheochromocytoma","volume":"170","author":"Siqueira","year":"2014","journal-title":"Eur. J. endocrinol.\/ Eur. Federation Endocrine Soc."},{"issue":"12","key":"10.1016\/j.semcancer.2021.03.035_bib0780","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1002\/ijc.27967","article-title":"The involvement of the RET variant G691S in medullary thyroid carcinoma enlightened by a meta-analysis study","volume":"132","author":"Lantieri","year":"2013","journal-title":"Int. J. Cancer Suppl."},{"issue":"3","key":"10.1016\/j.semcancer.2021.03.035_bib0785","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s12022-010-9125-8","article-title":"The frequency of selected polymorphic variants of the RET gene in patients with medullary thyroid carcinoma and in the general population of central Poland","volume":"21","author":"Sromek","year":"2010","journal-title":"Endocr. Pathol."},{"issue":"4","key":"10.1016\/j.semcancer.2021.03.035_bib0790","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1677\/ERC-09-0312","article-title":"The RET polymorphic allele S836S is associated with early metastatic disease in patients with hereditary or sporadic medullary thyroid carcinoma","volume":"17","author":"Siqueira","year":"2010","journal-title":"Endocr. Relat. Cancer"},{"issue":"6","key":"10.1016\/j.semcancer.2021.03.035_bib0795","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.surg.2010.09.004","article-title":"Single nucleotide polymorphisms act as modifiers and correlate with the development of medullary and simultaneous medullary\/papillary thyroid carcinomas in 2 large, non-related families with the RET V804M proto-oncogene mutation","volume":"148","author":"Shifrin","year":"2010","journal-title":"Surgery"},{"issue":"1","key":"10.1016\/j.semcancer.2021.03.035_bib0800","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1365-2265.2008.03491.x","article-title":"Evaluation of RET polymorphisms in a six-generation family with G533C RET mutation: specific RET variants may modulate age at onset and clinical presentation","volume":"71","author":"Tamanaha","year":"2009","journal-title":"Clin. Endocrinol. (Oxf)"},{"issue":"12","key":"10.1016\/j.semcancer.2021.03.035_bib0805","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1089\/thy.2008.0139","article-title":"The influence of gender, age, and RET polymorphisms on C-cell hyperplasia and medullary thyroid carcinoma","volume":"18","author":"Weinhaeusel","year":"2008","journal-title":"Thyroid"},{"issue":"2","key":"10.1016\/j.semcancer.2021.03.035_bib0810","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1158\/0008-5472.CAN-05-2995","article-title":"Polymorphisms in RET and its coreceptors and ligands as genetic modifiers of multiple endocrine neoplasia type 2A","volume":"66","author":"Lesueur","year":"2006","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.semcancer.2021.03.035_bib0815","first-page":"575","article-title":"Evaluation of the role of RET polymorphisms\/haplotypes as modifier loci for MEN 2, and analysis of the correlation with the type of RET mutation in a series of Spanish patients","volume":"17","author":"Fernandez","year":"2006","journal-title":"Int. J. Mol. Med."},{"issue":"11","key":"10.1016\/j.semcancer.2021.03.035_bib0820","doi-asserted-by":"crossref","first-page":"6232","DOI":"10.1210\/jc.2005-1278","article-title":"Polymorphisms in exon 13 and intron 14 of the RET protooncogene: genetic modifiers of medullary thyroid carcinoma?","volume":"90","author":"Baumgartner-Parzer","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.semcancer.2021.03.035_bib0825","first-page":"1814","article-title":"Polymorphisms G691S\/S904S of RET as genetic modifiers of MEN 2A","volume":"63","author":"Robledo","year":"2003","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.semcancer.2021.03.035_bib0830","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1034\/j.1399-0004.2003.00044.x","article-title":"Segregation of the V804L mutation and S836S polymorphism of exon 14 of the RET gene in an extended kindred with familial medullary thyroid cancer","volume":"63","author":"Patocs","year":"2003","journal-title":"Clin. Genet."},{"issue":"2","key":"10.1016\/j.semcancer.2021.03.035_bib0835","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/ijc.10298","article-title":"Genetic analysis of RET, GFR alpha 1 and GDNF genes in Spanish families with multiple endocrine neoplasia type 2A","volume":"99","author":"Gil","year":"2002","journal-title":"Int. J. Cancer Suppl."},{"issue":"6","key":"10.1016\/j.semcancer.2021.03.035_bib0840","doi-asserted-by":"crossref","first-page":"E1104","DOI":"10.1210\/jc.2013-2993","article-title":"Genome-wide copy number analysis in a family with p.G533C RET mutation and medullary thyroid carcinoma identified regions potentially associated with a higher predisposition to lymph node metastasis","volume":"99","author":"Araujo","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"11","key":"10.1016\/j.semcancer.2021.03.035_bib0845","doi-asserted-by":"crossref","first-page":"4367","DOI":"10.1210\/jc.2008-0912","article-title":"High resolution array-comparative genomic hybridization profiling reveals deoxyribonucleic acid copy number alterations associated with medullary thyroid carcinoma","volume":"93","author":"Ye","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.semcancer.2021.03.035_bib0850","first-page":"1241","article-title":"Germline and somatic mutations in an oncogene: RET mutations in inherited medullary thyroid carcinoma","volume":"56","author":"Marsh","year":"1996","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.semcancer.2021.03.035_bib0855","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.yexmp.2018.06.003","article-title":"Global DNA methylation profile in medullary thyroid cancer patients","volume":"105","author":"Ceolin","year":"2018","journal-title":"Exp. Mol. Pathol."},{"issue":"1\u20132","key":"10.1016\/j.semcancer.2021.03.035_bib0860","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.mce.2014.04.016","article-title":"Epigenetic-related gene expression profile in medullary thyroid cancer revealed the overexpression of the histone methyltransferases EZH2 and SMYD3 in aggressive tumours","volume":"392","author":"Sponziello","year":"2014","journal-title":"Mol. Cell. Endocrinol."},{"issue":"1","key":"10.1016\/j.semcancer.2021.03.035_bib0865","first-page":"1","article-title":"Frequent promoter methylation of tumor-related genes in sporadic and men2-associated pheochromocytomas, Experimental and clinical endocrinology & diabetes\u202f: official journal","volume":"113","author":"Dammann","year":"2005","journal-title":"German Soc. Endocrinol. German Diabetes Assoc."},{"issue":"9","key":"10.1016\/j.semcancer.2021.03.035_bib0870","doi-asserted-by":"crossref","first-page":"L49","DOI":"10.1530\/ERC-17-0349","article-title":"Penetrance of phaeochromocytoma in RET G533C carriers differs between South America and Europe","volume":"25","author":"Maciel","year":"2018","journal-title":"Endocr. Relat. Cancer"},{"issue":"8","key":"10.1016\/j.semcancer.2021.03.035_bib0875","doi-asserted-by":"crossref","first-page":"L63","DOI":"10.1530\/ERC-17-0189","article-title":"The penetrance of MEN2 pheochromocytoma is not only determined by RET mutations","volume":"24","author":"Castinetti","year":"2017","journal-title":"Endocr. Relat. Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.semcancer.2021.03.035_bib0880","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1186\/1756-6614-6-S1-S8","article-title":"The optimal range of RET mutations to be tested: European comments to the guidelines of the American Thyroid Association","volume":"6","author":"Fugazzola","year":"2013","journal-title":"Thyroid Res."},{"issue":"3","key":"10.1016\/j.semcancer.2021.03.035_bib0885","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/cen.12513","article-title":"Diagnosis and preoperative imaging of multiple endocrine neoplasia type 2: current status and future directions","volume":"81","author":"Taieb","year":"2014","journal-title":"Clin. Endocrinol."},{"issue":"3","key":"10.1016\/j.semcancer.2021.03.035_bib0890","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s12020-017-1300-y","article-title":"Accuracy of recommended sampling and assay methods for the determination of plasma-free and urinary fractionated metanephrines in the diagnosis of pheochromocytoma and paraganglioma: a systematic review","volume":"56","author":"D\u00e4rr","year":"2017","journal-title":"Endocrine"},{"issue":"2","key":"10.1016\/j.semcancer.2021.03.035_bib0895","doi-asserted-by":"crossref","first-page":"111","DOI":"10.14310\/horm.2002.1227","article-title":"Diagnosis of pheochromocytoma with special emphasis on MEN2 syndrome","volume":"8","author":"Pacak","year":"2009","journal-title":"Hormones (Athens, Greece)"},{"issue":"1","key":"10.1016\/j.semcancer.2021.03.035_bib0900","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/cpf.12391","article-title":"Role of positron emission tomography imaging in Multiple Endocrine Neoplasia syndromes","volume":"38","author":"July","year":"2018","journal-title":"Clin. Physiol. Funct. Imaging"},{"key":"10.1016\/j.semcancer.2021.03.035_bib0905","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/978-1-4419-0857-5_18","article-title":"Multiple endocrine neoplasia type 2: clinical manifestations and management","volume":"153","author":"Traugott","year":"2010","journal-title":"Cancer Treat. Res."},{"issue":"6","key":"10.1016\/j.semcancer.2021.03.035_bib0910","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1007\/s00268-009-0388-5","article-title":"Should routine analysis of the MEN1 gene be performed in all patients with primary hyperparathyroidism under 40 years of age?","volume":"34","author":"Skandarajah","year":"2010","journal-title":"World J. Surg."},{"issue":"2","key":"10.1016\/j.semcancer.2021.03.035_bib0915","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1002\/bjs.10746","article-title":"Long-term outcome of prophylactic thyroidectomy in children carrying RET germline mutations","volume":"105","author":"Machens","year":"2018","journal-title":"Br. J. Surg."},{"issue":"4","key":"10.1016\/j.semcancer.2021.03.035_bib0920","article-title":"Long-term outcome after DNA-based prophylactic neck surgery in children at risk of hereditary medullary thyroid cancer, best practice & research","volume":"33","author":"Machens","year":"2019","journal-title":"Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.semcancer.2021.03.035_bib0925","doi-asserted-by":"crossref","first-page":"T29","DOI":"10.1530\/ERC-17-0209","article-title":"A comprehensive review on MEN2B","volume":"25","author":"Castinetti","year":"2018","journal-title":"Endocr. Relat. Cancer"},{"issue":"8","key":"10.1016\/j.semcancer.2021.03.035_bib0930","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1210\/js.2018-00178","article-title":"Update on multiple endocrine neoplasia type 2: focus on medullary thyroid carcinoma","volume":"2","author":"Raue","year":"2018","journal-title":"J. Endocr. Soc."},{"issue":"29","key":"10.1016\/j.semcancer.2021.03.035_bib0935","doi-asserted-by":"crossref","first-page":"e1108","DOI":"10.1097\/MD.0000000000001108","article-title":"Postoperative complications after prophylactic thyroidectomy for very young patients with multiple endocrine neoplasia type 2: retrospective cohort analysis","volume":"94","author":"Kluijfhout","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.semcancer.2021.03.035_bib0940","doi-asserted-by":"crossref","first-page":"T41","DOI":"10.1530\/ERC-17-0202","article-title":"Advances in risk-oriented surgery for multiple endocrine neoplasia type 2","volume":"25","author":"Machens","year":"2018","journal-title":"Endocr. Relat. Cancer"},{"issue":"3","key":"10.1016\/j.semcancer.2021.03.035_bib0945","doi-asserted-by":"crossref","first-page":"E509","DOI":"10.1210\/jc.2010-1234","article-title":"Prognostic factors of disease-free survival after thyroidectomy in 170 young patients with a RET germline mutation: a multicenter study of the Groupe Francais d\u2019Etude des Tumeurs Endocrines","volume":"96","author":"Rohmer","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"12","key":"10.1016\/j.semcancer.2021.03.035_bib0950","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1210\/jcem.86.12.8070","article-title":"Guidelines for diagnosis and therapy of MEN type 1 and type 2","volume":"86","author":"Brandi","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.semcancer.2021.03.035_bib0955","doi-asserted-by":"crossref","first-page":"223","DOI":"10.21147\/j.issn.1000-9604.2017.03.08","article-title":"Is new American Thyroid Association risk classification for hereditary medullary thyroid carcinoma applicable to Chinese patients? A single-center study","volume":"29","author":"Zhang","year":"2017","journal-title":"Chin. J. Cancer Res."},{"issue":"3","key":"10.1016\/j.semcancer.2021.03.035_bib0960","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1007\/s00268-013-2413-y","article-title":"Role of preoperative basal calcitonin levels in the timing of prophylactic thyroidectomy in patients with germline RET mutations","volume":"38","author":"Lifante","year":"2014","journal-title":"World J. Surg."},{"issue":"2","key":"10.1016\/j.semcancer.2021.03.035_bib0965","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1210\/jc.2011-2046","article-title":"The timing of total thyroidectomy in RET gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 years experience at one single center","volume":"97","author":"Elisei","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.semcancer.2021.03.035_bib0970","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s12020-020-02332-2","article-title":"MEN2-related pheochromocytoma: current state of knowledge, specific characteristics in MEN2B, and perspectives","volume":"69","author":"Amodru","year":"2020","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.semcancer.2021.03.035_bib0975","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00259-019-04458-6","article-title":"EANM practice guideline for PET\/CT imaging in medullary thyroid carcinoma","volume":"47","author":"Giovanella","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"6","key":"10.1016\/j.semcancer.2021.03.035_bib0980","first-page":"861","article-title":"Management of familial hyperparathyroidism syndromes: MEN1, MEN2, MEN4, HPT-Jaw tumour, Familial isolated hyperparathyroidism, FHH, and neonatal severe hyperparathyroidism, best practice & research","volume":"32","author":"Cristina","year":"2018","journal-title":"Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.semcancer.2021.03.035_bib0985","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.surg.2005.09.020","article-title":"Selective arterial chemoembolization for hepatic metastases from medullary thyroid carcinoma","volume":"138","author":"Lorenz","year":"2005","journal-title":"Surgery"},{"issue":"7","key":"10.1016\/j.semcancer.2021.03.035_bib0990","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1210\/jc.2005-2401","article-title":"Chemoembolization for liver metastases from medullary thyroid carcinoma","volume":"91","author":"Fromigu\u00e9","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2021.03.035_bib0995","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2020.100282","article-title":"Bone metastases in thyroid cancer","volume":"21","author":"I\u00f1iguez-Ariza","year":"2020","journal-title":"J. Bone Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2021.03.035_bib1000","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/1078-0432.CCR-15-1127","article-title":"A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid Cancer","volume":"22","author":"Schlumberger","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"18_suppl","key":"10.1016\/j.semcancer.2021.03.035_bib1005","doi-asserted-by":"crossref","first-page":"14065","DOI":"10.1200\/jco.2007.25.18_suppl.14065","article-title":"Effect of sorafenib in symptomatic metastatic medullary thyroid cancer","volume":"25","author":"Kober","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2021.03.035_bib1010","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdw457.002","article-title":"Phase II trial of sorafenib for advanced or metastatic medullary thyroid carcinoma and anaplastic thyroid carcinoma","volume":"27","author":"Ito","year":"2016","journal-title":"Ann. Oncol."},{"issue":"14","key":"10.1016\/j.semcancer.2021.03.035_bib1015","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1200\/JCO.2009.25.0068","article-title":"Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer","volume":"28","author":"Lam","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.semcancer.2021.03.035_bib1020","doi-asserted-by":"crossref","first-page":"7061","DOI":"10.1158\/1078-0432.CCR-09-1241","article-title":"Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies","volume":"15","author":"Hong","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"29","key":"10.1016\/j.semcancer.2021.03.035_bib1025","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1200\/JCO.2007.15.9566","article-title":"Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study","volume":"26","author":"Cohen","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.semcancer.2021.03.035_bib1030","doi-asserted-by":"crossref","first-page":"567","DOI":"10.7326\/0003-4819-148-7-200804010-00027","article-title":"Response to sunitinib in medullary thyroid cancer","volume":"148","author":"Kelleher","year":"2008","journal-title":"Ann. Intern. Med."},{"issue":"21","key":"10.1016\/j.semcancer.2021.03.035_bib1035","doi-asserted-by":"crossref","first-page":"5260","DOI":"10.1158\/1078-0432.CCR-10-0994","article-title":"Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation","volume":"16","author":"Carr","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"15_suppl","key":"10.1016\/j.semcancer.2021.03.035_bib1040","doi-asserted-by":"crossref","first-page":"6058","DOI":"10.1200\/jco.2008.26.15_suppl.6058","article-title":"Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial","volume":"26","author":"Ravaud","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.semcancer.2021.03.035_bib1045","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.2008.18.7815","article-title":"Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer","volume":"27","author":"Schlumberger","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.semcancer.2021.03.035_bib1050","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1210\/jc.2013-3713","article-title":"A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H","volume":"99","author":"Bible","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.semcancer.2021.03.035_bib1055","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1089\/thy.2007.0120","article-title":"A phase II study of gefitinib in patients with advanced thyroid cancer","volume":"18","author":"Pennell","year":"2008","journal-title":"Thyroid"},{"issue":"2","key":"10.1016\/j.semcancer.2021.03.035_bib1060","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1530\/EJE-06-0695","article-title":"Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma","volume":"157","author":"Frank-Raue","year":"2007","journal-title":"Eur. J. endocrinol.\/ Eur. Federation Endocrine Soc."},{"issue":"9","key":"10.1016\/j.semcancer.2021.03.035_bib1065","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1210\/jc.2007-0649","article-title":"A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma","volume":"92","author":"de Groot","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"11","key":"10.1016\/j.semcancer.2021.03.035_bib1070","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1089\/thy.2018.0022","article-title":"Anlotinib for the treatment of patients with locally advanced or metastatic medullary thyroid cancer","volume":"28","author":"Sun","year":"2018","journal-title":"Thyroid"},{"issue":"15_suppl","key":"10.1016\/j.semcancer.2021.03.035_bib1075","doi-asserted-by":"crossref","first-page":"6019","DOI":"10.1200\/JCO.2019.37.15_suppl.6019","article-title":"Anlotinib treatment in locally advanced or metastatic medullary thyroid carcinoma: a multicenter, randomized, double-blind, placebo-controlled phase IIB trial","volume":"37","author":"Li","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.semcancer.2021.03.035_bib1080","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1210\/jc.2009-2461","article-title":"Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer","volume":"95","author":"Robinson","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.semcancer.2021.03.035_bib1085","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1200\/JCO.2009.23.6604","article-title":"Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer","volume":"28","author":"Wells","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.semcancer.2021.03.035_bib1090","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J.Clin.Oncol."},{"issue":"24","key":"10.1016\/j.semcancer.2021.03.035_bib1095","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1200\/JCO.19.02790","article-title":"Efficacy and safety of Vandetanib in progressive and symptomatic medullary thyroid Cancer: post hoc analysis from the ZETA trial","volume":"38","author":"Kreissl","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.semcancer.2021.03.035_bib1100","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1158\/1078-0432.CCR-17-2101","article-title":"Outcomes of children and adolescents with advanced hereditary medullary thyroid carcinoma treated with vandetanib","volume":"24","author":"Kraft","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"19","key":"10.1016\/j.semcancer.2021.03.035_bib1105","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1200\/JCO.2010.32.4145","article-title":"Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer","volume":"29","author":"Kurzrock","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"29","key":"10.1016\/j.semcancer.2021.03.035_bib1110","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.semcancer.2021.03.035_bib1115","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1002\/cncr.30252","article-title":"Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer","volume":"122","author":"Sherman","year":"2016","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.semcancer.2021.03.035_bib1120","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1093\/annonc\/mdx479","article-title":"Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma","volume":"28","author":"Schlumberger","year":"2017","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.semcancer.2021.03.035_bib1125","first-page":"335","article-title":"Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer, best practice & research","volume":"31","author":"Hadoux","year":"2017","journal-title":"Clini. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.semcancer.2021.03.035_bib1130","doi-asserted-by":"crossref","first-page":"R185","DOI":"10.1530\/ERC-15-0555","article-title":"Treatment of advanced thyroid cancer with targeted therapies: ten years of experience","volume":"23","author":"Viola","year":"2016","journal-title":"Endocr. Relat. Cancer"},{"issue":"1\u20132","key":"10.1016\/j.semcancer.2021.03.035_bib1135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mce.2013.06.025","article-title":"Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase","volume":"377","author":"Mologni","year":"2013","journal-title":"Mol. Cell. Endocrinol."},{"issue":"36","key":"10.1016\/j.semcancer.2021.03.035_bib1140","doi-asserted-by":"crossref","first-page":"6056","DOI":"10.1038\/sj.onc.1207810","article-title":"Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors","volume":"23","author":"Carlomagno","year":"2004","journal-title":"Oncogene"},{"issue":"394","key":"10.1016\/j.semcancer.2021.03.035_bib1145","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aah6144","article-title":"Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors","volume":"9","author":"Plenker","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"10","key":"10.1016\/j.semcancer.2021.03.035_bib1150","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1158\/1535-7163.MCT-16-0258","article-title":"Preclinical modeling of KIF5B-RET fusion lung adenocarcinoma","volume":"15","author":"Huang","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.semcancer.2021.03.035_bib1155","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41467-018-02994-7","article-title":"A secondary RET mutation in the activation loop conferring resistance to vandetanib","volume":"9","author":"Nakaoku","year":"2018","journal-title":"Nat. Commun."},{"issue":"15","key":"10.1016\/j.semcancer.2021.03.035_bib1160","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1158\/1078-0432.CCR-13-0071","article-title":"Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma","volume":"19","author":"Fox","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.semcancer.2021.03.035_bib1165","doi-asserted-by":"crossref","first-page":"T1","DOI":"10.1530\/ERC-17-0325","article-title":"Advances in the management of MEN2: from improved surgical and medical treatment to novel kinase inhibitors","volume":"25","author":"Wells","year":"2018","journal-title":"Endocr. Relat. Cancer"},{"issue":"8","key":"10.1016\/j.semcancer.2021.03.035_bib1170","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1093\/annonc\/mdy137","article-title":"Selective RET kinase inhibition for patients with RET-altered cancers","volume":"29","author":"Subbiah","year":"2018","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.semcancer.2021.03.035_bib1175","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-Altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.semcancer.2021.03.035_bib1180","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1158\/2159-8290.CD-18-0338","article-title":"Precision targeted therapy with BLU-667 for RET-Driven cancers","volume":"8","author":"Subbiah","year":"2018","journal-title":"Cancer Discov."},{"issue":"suppl_4","key":"10.1016\/j.semcancer.2021.03.035_bib1185","first-page":"S1026","article-title":"1913O - Results from the registrational phase I\/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)","volume":"31","author":"Hu","year":"2020","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.semcancer.2021.03.035_bib1190","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.semcancer.2021.03.035_bib1195","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9113507","article-title":"Advances in the management of medullary thyroid carcinoma: focus on peptide receptor radionuclide therapy","volume":"9","author":"Grossrubatscher","year":"2020","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.semcancer.2021.03.035_bib1200","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/snuc.2002.31028","article-title":"Cholecystokinin-B\/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies","volume":"32","author":"Behr","year":"2002","journal-title":"Semin. Nucl. Med."},{"issue":"10","key":"10.1016\/j.semcancer.2021.03.035_bib1205","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/apm.12584","article-title":"Expression of somatostatin receptor 2A in medullary thyroid carcinoma is associated with lymph node metastasis","volume":"124","author":"Herac","year":"2016","journal-title":"Apmis"},{"issue":"5","key":"10.1016\/j.semcancer.2021.03.035_bib1210","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1046\/j.1365-2265.2001.01175.x","article-title":"Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid","volume":"54","author":"Papotti","year":"2001","journal-title":"Clin. Endocrinol."},{"issue":"6","key":"10.1016\/j.semcancer.2021.03.035_bib1215","first-page":"469","article-title":"Leveraging the immune system to treat advanced thyroid cancers, the lancet","volume":"5","author":"French","year":"2017","journal-title":"Diabetes Endocrinol."},{"issue":"3","key":"10.1016\/j.semcancer.2021.03.035_bib1220","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00262-013-1505-8","article-title":"Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma","volume":"63","author":"Bilusic","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"issue":"15_suppl","key":"10.1016\/j.semcancer.2021.03.035_bib1225","doi-asserted-by":"crossref","first-page":"TPS3127","DOI":"10.1200\/jco.2013.31.15_suppl.tps3127","article-title":"A phase II study of a yeast-based therapeutic cancer vaccine, GI-6207, targeting CEA in patients with minimally symptomatic, metastatic medullary thyroid cancer","volume":"31","author":"Madan","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.semcancer.2021.03.035_bib1230","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1210\/jcem.86.10.7949","article-title":"Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination","volume":"86","author":"Schott","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.semcancer.2021.03.035_bib1235","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1200\/JCO.2003.02.135","article-title":"Dendritic cell-based vaccination in solid cancer","volume":"21","author":"Stift","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.semcancer.2021.03.035_bib1240","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1158\/1078-0432.CCR-03-0698","article-title":"Dendritic cell vaccination in medullary thyroid carcinoma","volume":"10","author":"Stift","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.semcancer.2021.03.035_bib1245","doi-asserted-by":"crossref","first-page":"R499","DOI":"10.1530\/ERC-18-0574","article-title":"Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives","volume":"26","author":"Ceolin","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"issue":"4","key":"10.1016\/j.semcancer.2021.03.035_bib1250","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jtho.2020.01.006","article-title":"RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-Driven malignancies","volume":"15","author":"Solomon","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.semcancer.2021.03.035_bib1255","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1159\/000499497","article-title":"Peptide receptor radionuclide therapy as a novel treatment for metastatic and invasive phaeochromocytoma and paraganglioma","volume":"109","author":"Mak","year":"2019","journal-title":"Neuroendocrinology"},{"issue":"12","key":"10.1016\/j.semcancer.2021.03.035_bib1260","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41416-019-0474-x","article-title":"A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial","volume":"120","author":"O\u2019Kane","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"12","key":"10.1016\/j.semcancer.2021.03.035_bib1265","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11912-017-0643-0","article-title":"Treatment for malignant pheochromocytomas and paragangliomas: 5 years of progress","volume":"19","author":"Jimenez","year":"2017","journal-title":"Curr. Oncol. Rep."},{"issue":"6","key":"10.1016\/j.semcancer.2021.03.035_bib1270","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1365-2265.2006.02659.x","article-title":"Determinants of life expectancy in medullary thyroid cancer: age does not matter","volume":"65","author":"de Groot","year":"2006","journal-title":"Clin. Endocrinol."},{"issue":"5","key":"10.1016\/j.semcancer.2021.03.035_bib1275","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/bjs.6075","article-title":"Prediction of lateral lymph node metastases in medullary thyroid cancer","volume":"95","author":"Machens","year":"2008","journal-title":"Br. J. Surg."},{"issue":"2","key":"10.1016\/j.semcancer.2021.03.035_bib1280","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/SLA.0b013e318268301d","article-title":"Prognostic impact of N staging in 715 medullary thyroid cancer patients: proposal for a revised staging system","volume":"257","author":"Machens","year":"2013","journal-title":"Ann. Surg."},{"issue":"9","key":"10.1016\/j.semcancer.2021.03.035_bib1285","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1002\/cncr.22244","article-title":"Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases","volume":"107","author":"Roman","year":"2006","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.semcancer.2021.03.035_bib1290","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1210\/jc.2004-1836","article-title":"Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level","volume":"90","author":"Machens","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.semcancer.2021.03.035_bib1295","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/BF00210956","article-title":"Prognostic factors in medullary thyroid carcinoma: evaluation of 741 patients from the German Medullary Thyroid Carcinoma Register","volume":"71","author":"Raue","year":"1993","journal-title":"Clin. Investig."},{"issue":"6","key":"10.1016\/j.semcancer.2021.03.035_bib1300","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/00005792-198411000-00001","article-title":"Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients","volume":"63","author":"Saad","year":"1984","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"10.1016\/j.semcancer.2021.03.035_bib1305","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/SLA.0b013e31813e66b9","article-title":"Long-term clinical and biochemical follow-up in medullary thyroid carcinoma: a single institution\u2019s experience over 20 years","volume":"246","author":"Cupisti","year":"2007","journal-title":"Ann. Surg."},{"issue":"4","key":"10.1016\/j.semcancer.2021.03.035_bib1310","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1365-2265.2009.03666.x","article-title":"Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis","volume":"72","author":"Meijer","year":"2010","journal-title":"Clin. Endocrinol."},{"issue":"11","key":"10.1016\/j.semcancer.2021.03.035_bib1315","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1210\/jc.2005-0044","article-title":"Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma","volume":"90","author":"Barbet","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.semcancer.2021.03.035_bib1320","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/(SICI)1097-0142(19970101)79:1<132::AID-CNCR19>3.0.CO;2-5","article-title":"Long-term follow-up of patients with medullary carcinoma of the thyroid","volume":"79","author":"Bergholm","year":"1997","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.semcancer.2021.03.035_bib1325","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJMoa043999","article-title":"Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A","volume":"353","author":"Skinner","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.semcancer.2021.03.035_bib1330","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1089\/thy.2007.0414","article-title":"Clinical and oncological features of children and young adults with multiple endocrine neoplasia type 2A","volume":"18","author":"Pu\u00f1ales","year":"2008","journal-title":"Thyroid"},{"issue":"8","key":"10.1016\/j.semcancer.2021.03.035_bib1335","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1002\/(SICI)1097-0142(20000415)88:8<1909::AID-CNCR21>3.0.CO;2-A","article-title":"Improved prediction of calcitonin normalization in medullary thyroid carcinoma patients by quantitative lymph node analysis","volume":"88","author":"Machens","year":"2000","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.semcancer.2021.03.035_bib1340","doi-asserted-by":"crossref","first-page":"E286","DOI":"10.1210\/jc.2013-3343","article-title":"Progression of medullary thyroid cancer in RET carriers of ATA class A and C mutations","volume":"99","author":"Machens","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.semcancer.2021.03.035_bib1345","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1210\/jc.2017-00317","article-title":"Medullary thyroid carcinoma in MEN2A: ATA moderate or high-risk RET mutations do not predict disease aggressiveness","volume":"102","author":"Voss","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.semcancer.2021.03.035_bib1350","doi-asserted-by":"crossref","first-page":"176","DOI":"10.4158\/EP13268.RA","article-title":"Genetics, diagnosis, and management of medullary thyroid carcinoma and pheochromocytoma\/paraganglioma","volume":"20","author":"Moraitis","year":"2014","journal-title":"Endocr. Pract."},{"issue":"11","key":"10.1016\/j.semcancer.2021.03.035_bib1355","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1055\/s-0043-120670","article-title":"Familial hyperparathyroidism - disorders of growth and secretion in hormone-secretory tissue","volume":"49","author":"Marx","year":"2017","journal-title":"Horm. Metab. Res."}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X21000857?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X21000857?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:50:56Z","timestamp":1760917856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X21000857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":271,"alternative-id":["S1044579X21000857"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2021.03.035","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiple endocrine neoplasia type 2: A review","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2021.03.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}